Related Experiment Video
Updated: Dec 31, 2025
Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
Criteria to Reevaluate Anti-drug Antibody Assay Cut Point Suitability in the Target Population
Charles Y Tan1, Gregory S Steeno2, Zhiping You2
1Worldwide Research Development and Medical, Pfizer Inc., 500 Arcola Rd, Collegeville, Pennsylvania, 19426, USA. charles.y.tan@pfizer.com.
Abstract:
After tier 1 and 2 cut points for anti-drug antibody (ADA) assays are derived during pre-study assay validation in a population, there is a need to verify the continued appropriateness of the previously derived cut points during sample analysis in the same or different populations, per FDA guidance (US HHS, FDA, CDER, CBER, 2019). Proper sample size-dependent criteria with statistical underpinning were derived and presented in this technical note to aid in assessing the appropriateness of tier 1 and tier 2 cut points, respectively.
More Related Videos
10:19High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
11:28Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015